Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Alvotech Ordinary Shares (ALVO)

https://www.alvotech.com

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/16/2022

Market Cap

3,890,548,440

Shares Outstanding

267,250,000

Weighted SO

266,023,001

Total Employees

N/A

Upcoming Earnings

09/04/2024

Beta

-0.0800

Last Div

0.0000

Range

8.29-18.0

Chg

0.9550

Avg Vol

124917

Mkt Cap

3890548440

Exch

NASDAQ

Country

IS

Phone

354 422 4500

DCF Diff

N/A

DCF

0.0000

Div Yield

0.0000

P/S

44.2108

EV Multiple

-15.9427

P/FV

-5.2184

Div Yield %

0.0000

P/E

-6.9556

PEG

-0.1683

Payout

0.0000

Current Ratio

1.1844

Quick Ratio

0.8107

Cash Ratio

0.2626

DSO

300.0839

DIO

237.5573

Op Cycle

537.6412

DPO

129.2276

CCC

408.4136

Gross Margin

-0.6104

Op Margin

-3.7667

Pretax Margin

-6.4847

Net Margin

-5.6168

Eff Tax Rate

0.1338

ROA

-0.4660

ROE

0.7240

ROCE

-0.4073

NI/EBT

0.8662

EBT/EBIT

1.7216

EBIT/Rev

-3.7667

Debt Ratio

0.9327

D/E

-1.5016

LT Debt/Cap

3.3382

Total Debt/Cap

2.9935

Int Coverage

-3.0235

CF/Debt

-0.3047

Equity Multi

-1.6099

Rec Turnover

1.2163

Pay Turnover

2.8245

Inv Turnover

1.5365

FA Turnover

0.2425

Asset Turnover

0.0830

OCF/Share

-1.1298

FCF/Share

-1.2693

Cash/Share

0.2429

OCF/Sales

-3.4256

FCF/OCF

1.1234

CF Coverage

-0.3047

ST Coverage

-6.1887

CapEx Coverage

-8.1015

Div&CapEx Cov

-8.1015

P/BV

-5.2184

P/B

-5.2184

P/S

44.2108

P/E

-6.9556

P/FCF

-11.4878

P/OCF

-11.4046

P/CF

-11.4046

PEG

-0.1683

P/S

44.2108

EV Multiple

-15.9427

P/FV

-5.2184

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 03, 23:02 Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers GlobeNewswire Inc. Jul 01, 23:54 Granting of Stock Options and Vesting of Restricted Share Units GlobeNewswire Inc. Jul 01, 23:54 Úthlutun nýrra kauprétta og afhending áunninna hlutabréfaréttinda GlobeNewswire Inc. Jun 05, 02:29 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million GlobeNewswire Inc. Jun 04, 23:55 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million GlobeNewswire Inc. Jun 04, 23:55 Alvotech lýkur lokuðu útboði á alls 7.500.000 sænskum heimildarskírteinum (SDR) og hlutabréfum á genginu 100 sænskar krónur fyrir hvert SDR og 1.320,83 íslenskar krónur fyrir hvern hlut, að heildarfjárhæð 750 milljónir sænskra króna GlobeNewswire Inc. May 26, 18:06 Aðalfundur Alvotech boðaður 25. júní 2025 GlobeNewswire Inc. May 26, 18:06 Alvotech Annual General Meeting to be held June 25, 2025 GlobeNewswire Inc. Mar 26, 22:36 Alvotech birtir metuppgjör fyrir árið 2024, sem sýnir mikla tekjuaukningu og kynnir nýjar áherslur og áfanga í rekstri félagsins GlobeNewswire Inc. May 21, 00:25 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. GlobeNewswire Inc. May 21, 00:25 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. GlobeNewswire Inc. May 21, 00:25 Alvotech og Teva Pharmaceuticals hefja sölu á líftæknilyfjahliðstæðunni Simlandi í Bandaríkjunum GlobeNewswire Inc. Jan 19, 11:30 Alvotech birtir upplýsingar um stöðu umsókna um markaðsleyfi fyrir AVT02 og AVT04 í Bandaríkjunum GlobeNewswire Inc. Jan 19, 11:30 Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 GlobeNewswire Inc. Jan 19, 11:30 Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 GlobeNewswire Inc. Jan 10, 03:30 Alvotech og STADA hljóta markaðsleyfi fyrir fyrstu líftæknilyfjahliðstæðuna við Stelara í Evrópu GlobeNewswire Inc. Jan 10, 03:30 STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara GlobeNewswire Inc. Jan 10, 03:30 STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara GlobeNewswire Inc. Jan 10, 03:30 Alvotech og STADA hljóta markaðsleyfi fyrir fyrstu líftæknilyfjahliðstæðuna við Stelara í Evrópu GlobeNewswire Inc. Jan 10, 03:30 STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara

Revenue Product Segmentation